Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Novel GLT-1 activators for the treatment of alcohol dependence: preclinical studies

Award Number: R01AA029674
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Novel GLT-1 activators for the treatment of alcohol dependence: preclinical studies - Abstract: Emerging evidence indicates that many aspects of ethanol (EtOH) and drug dependence involve changes in glutamate transmission in central reward brain regions, including the nucleus accumbens and medial prefrontal cortex. Upregulation of glutamate transporter 1 (GLT-1) in these brain regions with i.p. injections of several β-lactams, including ceftriaxone, attenuated EtOH intake and EtOH relapse behaviors in alcohol-preferring rats (P rats). GLT-1 is responsible for the uptake of the majority of extracellular glutamate. In addition, cystine/glutamate exchanger (xCT) is another astroglial protein involved in regulating glutamate homeostasis. The premise of this work is to pursue a very extensive preclinical study that will investigate the neuropharmacology of novel GLT- 1 upregulators, MC-100093, and derivatives as well as a non-antibiotic FDA-approved β-lactam, clavulanic acid (CLAV), which is a β-lactamase inhibitor in both continuous EtOH intake and EtOH relapse behavior. In this study, we will investigate novel -lactams (MC-100093 and derivatives), which do not have antibiotic action, on the expression of GLT-1 and xCT, and anti-inflammatory effects. The experimental goals are: (Aim 1) Investigate the pharmacokinetics.pharmacodynamics and target engagement of MC-100093 and, its derivatives and CLAV to determine dosing, and nominate efficacy biomarkers for subsequent use in P rats; (Aim 2) Investigate the pharmacological mechanisms of action of MC-100093 and its derivatives, and CLAV involving the upregulation of GLT-1 and xCT, and attenuation of neuroinflammation in P rats. Data generated from this project will show that novel drugs can upregulate GLT-1 expression and could have significant clinical implications for alcohol dependence and other neuropsychiatric disorders characterized by the hyperglutamatergic state as well as modulating neuroinflammation associated with an increase in extracellular glutamate in central brain regions that regulate drug dependence; and (Aim 3) to identify optimized, more lipophilic analogs of MC-100093 with drug-like properties and pharmacokinetic profiles that support once-dosing.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $416,030 )
2025	2025	UNIVERSITY OF TOLEDO	3000 ARLINGTON AVE	TOLEDO	OH	43614	LUCAS	USA	Alcohol Research Programs	000	4	7/25/2025	NON-COMPETING CONTINUATION	$416,030
														Subtotal = $416,030

Issue Date FY: 2024 ( Subtotal = $419,512 )
2024	2024	UNIVERSITY OF TOLEDO	3000 ARLINGTON AVE	TOLEDO	OH	43614	LUCAS	USA	Alcohol Research Programs	000	3	5/30/2024	NON-COMPETING CONTINUATION	$419,512
														Subtotal = $419,512

Issue Date FY: 2023 ( Subtotal = $430,579 )
2023	2023	UNIVERSITY OF TOLEDO, THE	3000 ARLINGTON AVE	TOLEDO	OH	43614	LUCAS	USA	Alcohol Research Programs	000	2	5/31/2023	NON-COMPETING CONTINUATION	$430,579
														Subtotal = $430,579

Issue Date FY: 2022 ( Subtotal = $437,019 )
2022	2022	UNIVERSITY OF TOLEDO, THE	3000 ARLINGTON AVE	TOLEDO	OH	43614	LUCAS	USA	Alcohol Research Programs	000	1	8/29/2022	NEW	$437,019
														Subtotal = $437,019

Grand Total All Awards = $1,703,140

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel GLT-1 activators for the treatment of alcohol dependence: preclinical studies

Award Number: R01AA029674

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer